# US 2001/0056081 A1 · Treatment of cerebrovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0056081 A1
- Document ID: US20010056081A1
- Status: Published application
- Kind: A1
- Application number: 09/820,199
- Filed: 2001-03-28
- Published: 2001-12-27
- Earliest claimed: 2000-03-28
- Assignees: Medicure International Inc.
- Inventors: Wasimul Haque; Rajat Sethi
- Web page: https://patentgrep.com/patent/US20010056081A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.

## Claims

### Claim 1

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one of pyridoxal-5′-phosphate, pyridoxal, pyridoxine, or pyridoxamine.

### Claim 2 (depends on 1)

The method of claim 1, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 3 (depends on 1)

The method of claim 1, wherein said compound is administered enterally or parenterally.

### Claim 4

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one compound of the formula
55
wherein
R1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy;
alkoxy;
dialkylamino;
alkanoyloxy;
alkanoyloxyaryl;
alkoxyalkanoyl;
alkoxycarbonyl;
dialkylcarbamoyloxy;
aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy; or
a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein said R1 is phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by one or more groups of C1-4 alkyl, C1-4 alkoxy, amino, hydroxy, halo, nitro, or C1-4 alkanoyloxy.

### Claim 6 (depends on 4)

The method of claim 4, wherein said R1 is (2-acetoxy-2-methyl)propanyl, dimethylamino, or 1-ethanoyloxy-1-methylethyl.

### Claim 7 (depends on 4)

The method of claim 4, wherein said R1 is tert-butyl.

### Claim 8 (depends on 4)

The method of claim 4, wherein said R1 is methoxy or ethoxy.

### Claim 9 (depends on 4)

The method of claim 4, wherein said R1 is toluyl, naphthyl, phenyl, acetylphenyl, or 1-ethanoyloxyphenyl.

### Claim 10 (depends on 4)

The method of claim 4, wherein said R1 is acetylsalicyl, dimethylamino, or 2,2-dimethylethyl.

### Claim 11 (depends on 4)

The method of claim 4, wherein said compound is 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine.

### Claim 12 (depends on 4)

The method of claim 4, wherein said compound is 2-methyl-3-β-naphthoyloxy-4-formyl-5-hydroxymethylpyridine.

### Claim 13 (depends on 4)

The method of claim 4, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 14 (depends on 4)

The method of claim 4, wherein said compound is administered enterally or parenterally.

### Claim 15

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one compound of the formula
56
wherein
R1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy;
alkoxy;
dialkylamino;
alkanoyloxy;
alkanoyloxyaryl;
alkoxyalkanoyl;
alkoxycarbonyl;
dialkylcarbamoyloxy;
aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy; and
R2 is a secondary amino group; or
a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein said R1 is phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by one or more groups of C1-4 alkyl, C1-4 alkoxy, amino, hydroxy, halo, nitro, or C1-4 alkanoyloxy.

### Claim 17 (depends on 15)

The method of claim 15, wherein said R1 is (2-acetoxy-2-methyl)propanyl, dimethylamino, or 1-ethanoyloxy-1-methylethyl.

### Claim 18 (depends on 15)

The method of claim 15, wherein said wherein R1 is tert-butyl.

### Claim 19 (depends on 15)

The method of claim 15, wherein said wherein R1 is methoxy or ethoxy.

### Claim 20 (depends on 15)

The method of claim 15, wherein said R1 is toluyl, naphthyl, phenyl, or 1-ethanoyloxyphenyl.

### Claim 21 (depends on 15)

The method of claim 15, wherein said R1 is dimethylamino, acetylsalicyl, or 2,2-dimethylethyl.

### Claim 22 (depends on 15)

The method of claim 15, wherein said R2 is a group of the formula
57
wherein R3 and R4 are each independently alkyl or when taken together form a ring with the nitrogen atom and which ring may optionally be interrupted by a nitrogen or oxygen atom.

### Claim 23 (depends on 15)

The method of claim 15, wherein said R2 is piperidino.

### Claim 24 (depends on 15)

The method of claim 15, wherein said R2 is morpholino or piperazino.

### Claim 25 (depends on 15)

The method of claim 15, wherein said compound is 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine.

### Claim 26 (depends on 15)

The method of claim 15, wherein said compound is 1-morpholino-1,3-dihydro-7-(β-naphthoyloxy)-6-methylfuro(3,4-c)pyridine.

### Claim 27 (depends on 15)

The method of claim 15, wherein said compound is 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine.

### Claim 28 (depends on 15)

The method of claim 15, wherein said compound is 1-morpholino-1,3-dihydro-7-(dimethylcarbamoyloxy-6-methylfuro(3,4-c)pyridine.

### Claim 29 (depends on 15)

The method of claim 15, wherein said compound is 1-morpholino-1,3-dihydro-7-acetylsalicyloxy-6-methylfuro (3,4-c)pyridine.

### Claim 30 (depends on 15)

The method of claim 15, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 31 (depends on 15)

The method of claim 15, wherein said compound is administered enterally or parenterally.

### Claim 32

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one compound of the formula
58
wherein
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3, —CO2R6 in which R6 is hydrogen, alkyl, or aryl; or
R2 is —CH2—O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1;
R3 is hydrogen and R4 is hydroxy, halo, alkoxy, alkanoyloxy, alkylamino or arylamino; or
R3 and R4 are halo; and
R5 is hydrogen, alkyl, aryl, aralkyl, or —CO2R7 in which R7 is hydrogen, alkyl, aryl, or aralkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein said R1 is hydrogen.

### Claim 34 (depends on 32)

The method of claim 32, wherein said R2 is —CH2OH, or —CH2—O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1.

### Claim 35 (depends on 32)

The method of claim 32, wherein said R3 is hydrogen and R4 is F, MeO—, or CH3C(O)O—.

### Claim 36 (depends on 32)

The method of claim 32, wherein said R3 and R4 are F.

### Claim 37 (depends on 32)

The method of claim 32, wherein said R5 is alkyl or aralkyl.

### Claim 38 (depends on 32)

The method of claim 32, wherein said R5 is t-butyl or benzyl.

### Claim 39 (depends on 32)

A method of claim 32, wherein said compound is
59

### Claim 40 (depends on 32)

The method of claim 32, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 41 (depends on 32)

The method of claim 32, wherein said compound is administered enterally or parenterally.

### Claim 42

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one compound of the formula
60
wherein
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3 or —CO2R5 in which R5 is hydrogen, alkyl, or aryl; or
R2 is —CH2—O-alkyl- (in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1);
R3 is hydrogen, alkyl, aryl, or aralkyl;
R4 is hydrogen, alkyl, aryl, aralkyl, or —CO2R6 in which R6 is hydrogen, alkyl, aryl, or aralkyl; and
n is 1 to 6;
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein said R1 is hydrogen.

### Claim 44 (depends on 42)

The method of claim 42, wherein said R2 is —CH2OH, or —CH2—O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1.

### Claim 45 (depends on 42)

The method of claim 42, wherein said R3 is hydrogen.

### Claim 46 (depends on 42)

The method of claim 42, wherein said R4 is alkyl or H.

### Claim 47 (depends on 42)

The method of claim 42, wherein said R4 is ethyl.

### Claim 48 (depends on 42)

The method of claim 42, wherein said compound is
61

### Claim 49 (depends on 42)

The method of claim 42, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 50 (depends on 42)

The method of claim 42, wherein said compound is administered enterally or parenterally.

### Claim 51

A method of treating cerebral ischemia, cerebral hemorrhage, ischemic stroke, or hemorrhagic stroke in a mammal comprising administering a therapeutically effective amount of at least one compound of the formula
62
in which
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3 or —CO2R8 in which R8 is hydrogen, alkyl, or aryl; or
R2 is —CH2—O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1;
R3 is hydrogen and R4 is hydroxy, halo, alkoxy or alkanoyloxy; or
R3 and R4 can be taken together to form ═O;
R5 and R6 are hydrogen; or
R5 and R6 are halo; and
R7 is hydrogen, alkyl, aryl, aralkyl, or —CO2R8 in which R8 is hydrogen, alkyl, aryl, or aralkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 51)

The method of claim 51, wherein said R1 is hydrogen.

### Claim 53 (depends on 51)

The method of claim 51, wherein said R2 is —CH2O or —CH2-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1.

### Claim 54 (depends on 51)

The method of claim 51, wherein said R4 is —OH or CH3C(O)O—.

### Claim 55 (depends on 51)

The method of claim 51, wherein said R3 and R4 taken together form ═O.

### Claim 56 (depends on 51)

The method of claim 51, wherein said R5 and R6 are F.

### Claim 57 (depends on 51)

The method of claim 51, wherein said R7 is alkyl.

### Claim 58 (depends on 51)

The method of claim 51, wherein said R7 is ethyl.

### Claim 59 (depends on 51)

The method of claim 51, wherein said compound is
63

### Claim 60 (depends on 51)

The method of claim 51, wherein said therapeutically effective amount is in a range of about 0.5-100 mg/kg per day of the mammal's body weight.

### Claim 61 (depends on 51)

The method of claim 51, wherein said compound is administered enterally or parenterally.

### Claim 62

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of pyridoxal-5′-phosphate, pyridoxal, pyridoxine, or pyridoxamine.

### Claim 63

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the formula
64
wherein
R1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy;
alkoxy;
dialkylamino;
alkanoyloxy;
alkanoyloxyaryl;
alkoxyalkanoyl;
alkoxycarbonyl;
dialkylcarbamoyloxy;
aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy; or
a pharmaceutically acceptable salt thereof.

### Claim 64

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the formula
65
wherein
R1 is alkyl or alkenyl, in which alkyl or alkenyl can be interrupted by nitrogen, oxygen, or sulfur, and can be substituted at the terminal carbon by hydroxy, alkoxy, alkanoyloxy, alkanoyloxyaryl, alkoxyalkanoyl, alkoxycarbonyl, or dialkylcarbamoyloxy;
alkoxy;
dialkylamino;
alkanoyloxy;
alkanoyloxyaryl;
alkoxyalkanoyl;
alkoxycarbonyl;
dialkylcarbamoyloxy;
aryl, aryloxy, arylthio, or aralkyl,in which aryl can be substituted by alkyl, alkoxy, amino, hydroxy,halo, nitro, or alkanoyloxy; and
R2 is a secondary amino group; or
a pharmaceutically acceptable salt thereof.

### Claim 65

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the formula
66
wherein
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3, —CO2R6 in which R6 is hydrogen, alkyl, or aryl; or
R2 is —CH2-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1;
R3 is hydrogen and R4 is hydroxy, halo, alkoxy, alkanoyloxy, alkylamino or arylamino; or
R3 and R4 are halo; and
R5 is hydrogen, alkyl, aryl, aralkyl, or —CO2R7 in which R7 is hydrogen, alkyl, aryl, or aralkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 66

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the formula
67
wherein
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3 or —CO2R5 in which R5 is hydrogen, alkyl, or aryl; or
R2 is —CH2—O-alkyl- (in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1);
R3 is hydrogen, alkyl, aryl, or aralkyl;
R4 is hydrogen, alkyl, aryl, aralkyl, or —CO2R6 in which R6 is hydrogen, alkyl, aryl, or aralkyl; and
n is 1 to 6;
or a pharmaceutically acceptable salt thereof.

### Claim 67

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the formula
68
in which
R1 is hydrogen or alkyl;
R2 is —CHO, —CH2OH, —CH3 or —CO2R8 in which R8 is hydrogen, alkyl, or aryl; or R2 is —CH2—O-alkyl- in which alkyl is covalently bonded to the oxygen at the 3-position instead of R1;
R3 is hydrogen and R4 is hydroxy, halo, alkoxy or alkanoyloxy; or
R3 and R4 can be taken together to form ═O;
R5 and R6 are hydrogen; or
R5 and R6 are halo; and
R7 is hydrogen, alkyl, aryl, aralkyl, or —CO2R8 in which R8 is hydrogen, alkyl, aryl, or aralkyl;
or a pharmaceutically acceptable salt thereof.
